Is There Still a Place for Extraanatomic Axillofemoral Bypass in the Endovascular Era?
Clicks: 1
ID: 315792
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #330 of 432 articles by views in the british journal of surgery
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background In an era of rapid advances in endovascular surgery, axillofemoral bypass has become a rare solution for lower limb revascularization. Aims This evolution in the indication for axillofemoral bypass makes analyzing outcomes of these procedures even more important. Methods Consecutive patients who underwent uni- or bifemoral axillofemoral bypass between March 2018 and May 2024 at a single center were analyzed. Outcomes were primary patency, mortality and major amputation rate at 30 days and one year postoperatively. Results Twelve patients were identified. Four (33%) received axillobifemoral bypass, and the remaining patients received axillounifemoral bypass. Median age was 75 (range 57 - 88) years, and 66% were male. All patients had aortoiliac occlusive disease and more than one cardiovascular risk factor. Most patients (75%) were American Society of Anesthesiologists (ASA) category III and three patients (25%) were ASA category IV. Axillofemoral bypass was an urgent procedure in half of the patients due to acute limb ischemia. The other half underwent elective procedures for disabling claudication. Mean operation time was 165 minutes (range 40–309 minutes), and the mean blood loss was 375 mL (range 50–1500 mL). Eight patients (66%) required simultaneous outflow optimization by femoral endarterectomy and patchplasty. One of these patients also received profundopopliteal bypass. Primary patency at 30 days was 100%. One bypass occluded after 10 months, all others were patent at one year. Mortality at 30 days and one year was 8% and 33%, respectively. Two patients (17%) required major amputation within one year of follow-up. Conclusion Although axillofemoral bypass surgery has become less common, it may still be a safe and feasible option for polymorbid patients even in emergency situations. Despite the advances in endovascular techniques, we should keep this option in mind.FigureAxillobifemoral bypass in a patient with extended aortoiliac occlusive diseaseFor image description, please refer to the figure legend and surrounding text.
| Reference Key |
openalex_W7163370771
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | F Möhle, D Müller, S Weiss, P Kissling |
| Journal | the british journal of surgery |
| Year | 2026 |
| DOI |
10.1093/bjs/znag055.071
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.